Invasive Bladder Cancer Clinical Trials

69 recruitingLast updated: June 21, 2026

There are 69 actively recruiting invasive bladder cancer clinical trials across 27 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Phase 4. Top locations include New York, New York, United States, San Antonio, Texas, United States, Dallas, Texas, United States. Updated daily from ClinicalTrials.gov.


Invasive Bladder Cancer Trials at a Glance

69 actively recruiting trials for invasive bladder cancer are listed on ClinicalTrialsFinder across 6 cities in 27 countries. The largest study group is Phase 2 with 30 trials, with the heaviest enrollment activity in New York, San Antonio, and Dallas. Lead sponsors running invasive bladder cancer studies include Ferring Pharmaceuticals, Johns Hopkins University, and Memorial Sloan Kettering Cancer Center.

Browse invasive bladder cancer trials by phase

Treatments under study

About Invasive Bladder Cancer Clinical Trials

Looking for clinical trials for Invasive Bladder Cancer? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Invasive Bladder Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Invasive Bladder Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 69 trials

Recruiting
Phase 3

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

Intermediate Risk Non-Muscle Invasive Bladder Cancer
Ferring Pharmaceuticals454 enrolled101 locationsNCT06510374
Recruiting
Phase 3

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Ferring Pharmaceuticals250 enrolled75 locationsNCT06545955
Recruiting
Phase 1Phase 2

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

Non Muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC32 enrolled13 locationsNCT06637423
Recruiting
Phase 2

EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC

Muscle Invasive Bladder Cancer (MIBC)
Peking University Third Hospital58 enrolled1 locationNCT07647289
Recruiting
Phase 2

Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer

Non-Muscle-Invasive Bladder Cancer (NMIBC)
Shanxi Province Cancer Hospital30 enrolled1 locationNCT07646145
Recruiting

Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy

Bladder CancerNon Muscle Invasive Bladder Cancer
Photocure500 enrolled4 locationsNCT07144319
Recruiting
Phase 2

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Muscle Invasive Bladder Cancer
Astellas Pharma Global Development, Inc.240 enrolled9 locationsNCT07475806
Recruiting
Phase 2

Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy

Non Muscle Invasive Bladder Cancer
BLATAM37 enrolled1 locationNCT06972615
Recruiting
Phase 1Phase 2

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

Non Muscle Invasive Bladder Cancer
SURGE Therapeutics75 enrolled20 locationsNCT05710848
Recruiting

Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging

Bladder CancerUrothelial Carcinoma (UC)Muscle Invasive Bladder Cancer (MIBC)+1 more
Oslo University Hospital150 enrolled1 locationNCT07602010
Recruiting
Phase 2

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Non Muscle Invasive Bladder Cancer
Protara Therapeutics131 enrolled66 locationsNCT05951179
Recruiting
Phase 3

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

Non Muscle Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center125 enrolled9 locationsNCT06929286
Recruiting
Phase 1

Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment

Non Muscle Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center55 enrolled7 locationsNCT05126472
Recruiting
Phase 2

Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance

Non Muscle Invasive Bladder Cancer
White River Junction Veterans Affairs Medical Center240 enrolled9 locationsNCT05796375
Recruiting
Not Applicable

mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer

Muscle Invasive Bladder CancerUrothelial Bladder Cancer
University of California, Irvine30 enrolled1 locationNCT06335667
Recruiting
Phase 2

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

Urothelial CarcinomaMuscle Invasive Bladder Cancer
University of California, Irvine23 enrolled1 locationNCT06682728
Recruiting
Phase 1Phase 2

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Non-muscle Invasive Bladder Cancer With Carcinoma in SituSuperficial Bladder Cancer
enGene, Inc.350 enrolled101 locationsNCT04752722
Recruiting

AFU Registry of the Therapeutic Management and Follow-up of Non-Muscle-Invasive Bladder Cancer

Non Muscle Invasive Bladder Cancer
Association Francaise d'Urologie8,000 enrolled44 locationsNCT05002556
Recruiting
Phase 2

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Non Muscle Invasive Bladder CancerHigh-grade Ta/ T1 Papillary Disease Bladder Cancer
Lepu Biopharma Co., Ltd.16 enrolled14 locationsNCT07283835
Recruiting

Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2

Bladder CancerNon-Muscle-Invasive Bladder Cancer (NMIBC)Recurrent Bladder Cancer
University of Washington408 enrolled6 locationsNCT07225127